Corbus Pharmaceuticals Holdings, Inc. (CRBP) vs The Joint Corp. (JYNT)
A side-by-side comparison of Corbus Pharmaceuticals Holdings, Inc. and The Joint Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$5.88HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
JYNT
The Joint Corp.
$7.19HealthcareDelayed quote: Oct 6, 2026, 11:30 AM EDT
Total return — CRBP vs JYNT
growth of $100 · dividends reinvested · last 10yCRBP -97.2% (-30.1%/yr)JYNT +195.9% (+11.5%/yr)JYNT compounded faster over this window
Log scale — wide-divergence pair
CRBP JYNT
CRBP vs JYNT: by the numbers
- •CRBP is the larger company ($109M vs $102M market cap).
- •JYNT is profitable (6.49% net margin) while CRBP runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | CRBP | JYNT |
|---|---|---|
| P/E ratio | N/A | 27.10 |
| Forward P/E | N/A | 29.94 |
| P/S ratio | N/A | 1.75 |
| P/B ratio | 1.07 | 6.46 |
| EV / EBITDA | N/A | 26.04 |
| FCF yield | N/A | 4.13% |
Profitability
| Metric | CRBP | JYNT |
|---|---|---|
| Gross margin | 0.00% | 81.08% |
| Operating margin | 0.00% | 2.45% |
| Net margin | 0.00% | 6.49% |
| ROE | -99.67% | 23.96% |
| ROIC | -101.30% | 5.11% |
Growth (annualized)
| Metric | CRBP | JYNT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -3.57% |
| EPS CAGR (5Y) | N/A | -27.37% |
| FCF CAGR (5Y) | N/A | -16.35% |
| Total return CAGR (5Y) | -28.32% | -40.34% |
Frequently asked
- Is CRBP or JYNT more profitable?
- JYNT runs the higher net margin — CRBP at 0.00% versus JYNT at 6.49%.
- How have CRBP and JYNT total returns compared?
- Over the past 10 years, CRBP delivered -31.74% and JYNT delivered 11.23% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Joint P/E ratioCorbus Pharmaceuticals ROEJoint ROECorbus Pharmaceuticals operating marginJoint operating marginCorbus Pharmaceuticals revenue growthJoint revenue growthCorbus Pharmaceuticals free cash flowJoint free cash flow
Corbus Pharmaceuticals & Joint appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.